Some reports demonstrated among patients with ALL representing ETV6/RUNX1-positive, there was an associated 5-year EFS rate of 80–97%, significantly higher than other subtypes, which revealed excellent outcome (7–10). This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.